Medexus Pharmaceuticals (TSE:MDP) Given New C$6.25 Price Target at Ventum Financial

Medexus Pharmaceuticals (TSE:MDP) had its target price upped by equities researchers at Ventum Financial from C$5.00 to C$6.25 in a report issued on Thursday,BayStreet.CA reports. The firm presently has a “buy” rating on the stock. Ventum Financial’s price objective would indicate a potential upside of 62.34% from the company’s current price.

MDP has been the subject of a number of other research reports. Stifel Nicolaus raised their price objective on Medexus Pharmaceuticals from C$4.50 to C$6.00 in a research report on Thursday. Raymond James upgraded Medexus Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a C$4.00 price target for the company in a report on Wednesday, January 8th. Ventum Cap Mkts raised Medexus Pharmaceuticals to a “strong-buy” rating in a report on Friday, January 17th. Leede Financial raised shares of Medexus Pharmaceuticals from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, January 22nd. Finally, Alliance Global Partners upgraded shares of Medexus Pharmaceuticals to a “strong-buy” rating in a research report on Monday, December 23rd. Two investment analysts have rated the stock with a buy rating and five have given a strong buy rating to the stock. According to data from MarketBeat.com, Medexus Pharmaceuticals has an average rating of “Strong Buy” and an average price target of C$6.13.

Medexus Pharmaceuticals Stock Performance

MDP opened at C$3.85 on Thursday. The stock has a market capitalization of C$94.44 million, a price-to-earnings ratio of 77.00 and a beta of 1.96. The company has a fifty day moving average of C$3.44 and a 200 day moving average of C$2.78. Medexus Pharmaceuticals has a fifty-two week low of C$1.47 and a fifty-two week high of C$5.56.

Medexus Pharmaceuticals Company Profile

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.